Nexstim Plc · OMXHEX:NXTMH
Nexstim — H1 2020 Earnings Presentation
6 slides from Nexstim's earnings presentation, Aug 14, 2020
Slide 1: Nexstim. Personalised depression treatment.
Nexstim. Personalised depression treatment. Mikko Karvinen| CEO | Nexstim Plc Joonas Juokslahti | CFO | Nexstim Plc Nexstim Plc H1 2020 Half-Yearly Report Webinar, 14 August 2020
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: H1 2020 Highlights
H1 2020 Highlights • Focused on minimizing the effect of COVID-19 pandemic as well as updating company strategy. Considering the difficult business environment, good progress with four new NBS systems sold, three in the US one in the EU and a total of five new NBT® systems installed to clinics in th
Slide 4: Key Performance Indicators H1 2020
Key Performance Indicators H1 2020 • All time high H1 Net Sales EUR in thousands 1-6/2020 • Total Net Sales increased by +33% 6 months • NBS sales EUR 0.9M (+47%) Net sales 1,614.5 • NBT sales EUR 0.7M (+18%) Personnel expenses -1,597.3 • 100% recurring revenue Other operating expenses -1,363.7 • Su
Slide 5: Key Strategic Objectives for 2020
Key Strategic Objectives for 2020 • Decrease the operating loss with focus on achieving profitable revenue growth and strict management of operating expenses • Start two new pilot studies in treating severe depression and/or chronic pain patients with accelerated therapy treatment protocols • Develo
Slide 6: Thank you!
Nexstim Thank you!